Streetbeat News

Products Services

ALPN

VRTX

Vertex Pharmaceuticals Incorporated (VRTX) is set to acquire Alpine Immune Sciences Inc (ALPN) for approximately $4.9 billion, or $65 per share, in cash. This acquisition aims to expand Vertex's portfolio beyond its cystic fibrosis franchise into kidney disease treatments, with Alpine's lead molecule, povetacicept (ALPN-303), showing promise in IgA nephropathy (IgAN). The deal, expected to close in Q2 2024, aligns with Vertex's strategy of targeting diseases with high unmet need. Alpine's recent Phase 1b/2a study of povetacicept reported significant reductions in proteinuria and hematuria in IgAN patients.

Portfolio Pulse from Vandana Singh

April 11, 2024 | 1:01 pm

HRMY

Harmony Biosciences' stock is trading higher following the announcement of an exclusive licensing agreement with Bioprojet for TPM-1116, aimed at treating narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:54 pm

GILD

UNH

VERV

The article highlights the top 3 oversold health care stocks, suggesting potential investment opportunities. Verve Therapeutics, UnitedHealth Group, and Gilead Sciences are featured for their low RSI values, indicating they may be undervalued. Recent developments and stock performance for each company are discussed, providing a basis for their inclusion in the list of stocks that could rescue portfolios this quarter.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 12:46 pm

NEOG

Neogen Corporation has launched its Farm Fluid MAX disinfectant in the Great Britain livestock and poultry markets, aiming to enhance biosecurity measures in these sectors.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:46 pm

FCOM

META

XLC

Meta Platforms, Inc. (NASDAQ:META) has introduced new safety features on Instagram to protect teenagers from 'sextortion' scams, including obscuring nude images and providing direct reporting options. The initiative aims to enhance online safety for teens, with a global launch planned for teen accounts. Meta's move, which does not extend to WhatsApp and Messenger, follows previous efforts to safeguard teen users and comes amid broader scrutiny over child safety on its platforms. Meta's stock has seen significant growth, with over 143% gain in the last 12 months, and is part of ETFs like The Communication Services Select Sector SPDR Fund (NYSE:XLC) and Fidelity MSCI Communication Services Index ETF (NYSE:FCOM).

Portfolio Pulse from Anusuya Lahiri

April 11, 2024 | 12:44 pm

INBS

Intelligent Bio Solutions' subsidiary, Fingerprinting, has been granted a new European patent with unitary effect for its DSR-Plus Cartridge Reader. This development could enhance the company's competitive edge in the European market by protecting its innovative technology.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:44 pm

QTI

QT Imaging's Breast Acoustic CT Scanner will now be available at the Center For New Medicine, enhancing personalized prevention and breast cancer detection efforts.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:43 pm

ADBE

GGME

PNQI

Adobe Inc is expanding its AI capabilities by acquiring video datasets for its text-to-video generator, competing with OpenAI's technology. Adobe is offering $120 for video submissions from its community to enhance its AI training dataset. The initiative is part of Adobe's broader strategy to integrate generative AI across its creative tools. Adobe's stock is accessible through Invesco Next Gen Media And Gaming ETF (GGME) and Invesco Nasdaq Internet ETF (PNQI), and it saw a slight decrease of 0.35% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

April 11, 2024 | 12:41 pm

TEVA

Teva Pharmaceutical Industries announced successful results from a Phase 3 study of AJOVY, meeting all critical efficacy endpoints through hierarchical testing, indicating significant efficacy and safety.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:38 pm

CRMD

Two abstracts from CorMedix have been accepted for presentation at the upcoming SHEA (Society for Healthcare Epidemiology of America) conference. This acceptance is a significant recognition for CorMedix's research and could potentially impact its visibility and credibility in the healthcare sector.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:37 pm